HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Carl R Illig Selected Research

Reperfusion Injury

6/2004A novel series of potent and selective small molecule inhibitors of the complement component C1s.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Carl R Illig Research Topics

Disease

2Arthritis (Polyarthritis)
11/2011 - 03/2008
1Neoplasm Metastasis (Metastasis)
11/2009
1Neoplasms (Cancer)
11/2009
1Adenocarcinoma of Lung
11/2009
1Carcinoma (Carcinomatosis)
11/2009
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/2009
1Hereditary Angioedemas
06/2004
1Reperfusion Injury
06/2004

Drug/Important Bio-Agent (IBA)

24- cyano- N- (2- (1- cyclohexen- 1- yl)- 4- (1- ((dimethylamino)acetyl)- 4- piperidinyl)phenyl)- 1H- imidazole- 2- carboxamideIBA
11/2011 - 11/2009
2Phosphotransferases (Kinase)IBA
11/2009 - 03/2008
1Collagen Type II (Type II Collagen)IBA
11/2011
1tyrosine receptor (receptor, tyrosine)IBA
11/2009
1Zoledronic Acid (Zometa)FDA Link
11/2009
1Macrophage Colony-Stimulating FactorIBA
11/2009
1Macrophage Colony-Stimulating Factor Receptor (Receptor, Macrophage Colony Stimulating Factor)IBA
11/2009
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
11/2009
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
11/2009
1Biomarkers (Surrogate Marker)IBA
11/2009
1CollagenIBA
03/2008
1Complement System Proteins (Complement)IBA
06/2004